Visit
Spinal muscular atrophy (SMA) is a severe genetic disease associated with mutations in the SMN1 gene (SMA5q). The pathological characteristics…
Following the termination of the GENERATION HD1 trial in March 2021, Roche have now announced plans for a new Phase…
The Food and Drug Administration (FDA) approved ublituximab for the treatment of relapsing forms of multiple sclerosis (MS), making it…
New data presented at the American Epilepsy Society (AES) 2022 annual meeting has demonstrated that the presence of active seizures…
The MR CLEAN-LATE prospective, randomized study of over 500 patients with acute ischemic stroke showed that endovascular thrombectomy (EVT) provides…
On September 29, 2022, the Food and Drug Administration (FDA) approved AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS),…
Current guidelines warn against the use of intravenous thrombolysis in patients with ischemic stroke and recent direct oral anticoagulant (DOAC)…
The first interim data has been published from a Phase I/II trial testing the safety and tolerability of AMT-130. If…
Myasthenia gravis (MG) is a rare disorder, exhibiting the archetypic traits of both the neuromuscular junction and autoantibody-mediated disease –…
A record-breaking study into the relationship between Epstein-Barr virus (EBV) infection and multiple sclerosis (MS) onset has revealed a 32-fold…
Get the latest blog headlines delivered to your inbox.
